Merck KGaA (FRA:MRK)‘s stock had its “buy” rating reaffirmed by equities researchers at DZ Bank in a report released on Wednesday, Borsen Zeitung reports.

Several other equities research analysts have also recently weighed in on the company. Warburg Research set a €103.00 ($119.77) target price on Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Wednesday. Morgan Stanley set a €96.00 ($111.63) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, June 18th. Nord/LB set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a “buy” rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of €100.67 ($117.05).

FRA MRK traded down €1.60 ($1.86) on Wednesday, hitting €93.52 ($108.74). 278,984 shares of the company’s stock were exchanged. The business has a 50-day moving average price of €93.68. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Futures Contract

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.